Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs.
HCV
HCV late relapse
HCV reinfection
NGS
hepatitis C virus
next-generation sequencing
phylogenetic
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
16 06 2021
16 06 2021
Historique:
received:
19
04
2021
revised:
09
06
2021
accepted:
14
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
17
8
2021
Statut:
epublish
Résumé
The risk of hepatitis C virus (HCV) recurrence after direct-acting antiviral (DAA) treatment is <0.5%. However, the distinction between HCV RNA late relapse and reinfection still represents a challenge in virological diagnostics. The aim of this study was to employ next-generation sequencing (NGS) to investigate HCV RNA recurrence in patients achieving a sustained virologic response (SVR) at least six months post-treatment. NGS was performed on plasma samples from six HCV-positive patients (Pt1-6) treated with DAA. NGS of HCV NS5B was analyzed before treatment (T0), after HCV RNA rebound (T1), and, for Pt3, after a second rebound (T2). Reinfection was confirmed for Pt5, and for the first rebound observed in Pt3. Conversely, viral relapse was observed when comparing T0 and T1 for Pt6 and T1 and T2 for Pt3. Z-scores were calculated and used to predict whether HCV-positive patient samples at different time points belonged to the same quasispecies population. A low
Identifiants
pubmed: 34208646
pii: v13061151
doi: 10.3390/v13061151
pmc: PMC8235384
pii:
doi:
Substances chimiques
Antiviral Agents
0
RNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Lancet. 2011 Aug 13;378(9791):571-83
pubmed: 21802134
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176
pubmed: 28404132
J Hepatol. 2018 Nov;69(5):1007-1014
pubmed: 30142429
PLoS One. 2017 Jul 27;12(7):e0181683
pubmed: 28750044
J Viral Hepat. 2012 Feb;19(2):120-7
pubmed: 22239501
Virology. 2016 Jun;493:227-37
pubmed: 27060566
Clin Infect Dis. 2016 Mar 15;62(6):683-694
pubmed: 26787172
J Infect Dis. 2020 Jul 6;222(3):488-498
pubmed: 32150621
J Hepatol. 2020 Nov;73(5):1170-1218
pubmed: 32956768
Virus Evol. 2019 Jan 30;5(1):vey041
pubmed: 30723551
J Antimicrob Chemother. 2016 Mar;71(3):739-50
pubmed: 26679249
Mol Biol Evol. 2015 Jan;32(1):268-74
pubmed: 25371430
Clin Liver Dis. 2015 Nov;19(4):707-16, vii
pubmed: 26466657
PLoS One. 2016 May 19;11(5):e0155869
pubmed: 27196673
PLoS One. 2011;6(7):e22245
pubmed: 21799802
Bioinformatics. 2012 Dec 1;28(23):3150-2
pubmed: 23060610
Mol Biol Evol. 2018 Jun 1;35(6):1547-1549
pubmed: 29722887
Lancet Gastroenterol Hepatol. 2017 May;2(5):325-336
pubmed: 28397696
Gastroenterology. 2017 Feb;152(3):550-553.e8
pubmed: 27838287
Clin Infect Dis. 2017 Jan 1;64(1):44-52
pubmed: 27737953
AIDS. 2013 Oct 23;27(16):2551-7
pubmed: 23736152
Infect Dis (Lond). 2015 Aug;47(8):555-62
pubmed: 25851241
Int J Antimicrob Agents. 2020 Jul;56(1):105562
pubmed: 30315919
Virus Res. 2017 Jul 15;239:115-125
pubmed: 28040474
Clin Med (Lond). 2016 Apr;16(2):189-92
pubmed: 27037392
EBioMedicine. 2018 Nov;37:374-381
pubmed: 30448155
Liver Int. 2019 May;39(5):844-853
pubmed: 30554459
J Hepatol. 2018 Sep;69(3):718-735
pubmed: 29777749
BMC Bioinformatics. 2015 Jan 16;16:10
pubmed: 25592313
Clin Infect Dis. 2009 Nov 1;49(9):1397-401
pubmed: 19814621
Sci Rep. 2017 Aug 14;7(1):8106
pubmed: 28808243
J Virol. 2004 Jun;78(11):5867-74
pubmed: 15140984
J Hepatol. 2020 Apr;72(4):643-657
pubmed: 31785345
Nucleic Acids Res. 2004 Mar 19;32(5):1792-7
pubmed: 15034147